Ensign Peak Advisors’s Praxis Precision Medicines PRAX Stock Holding History
Bought
Maintained
Sold
Other funds holding PRAX
BBA
Ensign Peak Advisors's PRAX Position: Q3 2026 in Review
Ensign Peak Advisors increased its Praxis Precision Medicines (PRAX) stake by 14% in Q3 2026, buying an estimated $3.36M and bringing the position to 83,099 shares worth $24.2M. The position accounts for 0.04% of the portfolio, ranked #306.
Ensign Peak Advisors first reported a position in PRAX in Q4 2021 and has held it in 7 quarters since. The position peaked at $24.4M in Q2 2026. 329 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.
- Ensign Peak Advisors held 83,099 shares of Praxis Precision Medicines worth $24.2M as of Q3 2026.
- Ensign Peak Advisors bought 10,147 Praxis Precision Medicines shares in Q3 2026, an estimated $3.36M.
- Praxis Precision Medicines made up 0.04% of Ensign Peak Advisors's portfolio in Q3 2026, its #306 holding.
- Ensign Peak Advisors first reported a position in Praxis Precision Medicines in Q4 2021 and has held it in 7 quarters since.
- Ensign Peak Advisors's Praxis Precision Medicines position peaked at $24.4M in Q2 2026.
- 329 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.
Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.